Promising pipeline drugs include rubitecan, currently in stage III development with SuperGen,Irofulven, Virulizin and Imc-c225. The limited range of marketed treatments available meansthat drugs launched for pancreatic cancer in the next few years will meet little in the way ofcompetition.However, the anticipated launch of rubitecan in 2002 will cause a fundamental shift in thedynamics of the market, with uptake increasingly impacted by position to approval andpromotional strength
